NCT03412877 2026-03-17
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
10 trialsNCT05191472 2025-01-15
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
University of California, San Francisco
Phase 2 Terminated
NCT05204160 2024-07-03
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Emory University
Phase 2 Withdrawn
NCT03506360 2024-01-09
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT04258683 2023-08-29
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Canadian Myeloma Research Group
Phase 2 Withdrawn
NCT02906332 2023-08-22
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Hackensack Meridian Health
Phase 2 Terminated
NCT04361851 2022-04-26
Study of Dara-Pembro for Multiple Myeloma Patients
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT02636010 2020-04-29
Pembrolizumab (MK-3475) in MM Patients With Residual Disease
PETHEMA Foundation
Phase 2 Completed
NCT03221634 2019-03-25
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT02331368 2018-07-27
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
University of Michigan Rogel Cancer Center
Phase 2 Completed